m+Medelevator.RU
← Поиск публикаций
Nature cancer · 2026

Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Vassy Jason L, Dornisch Anna M, Karunamuni Roshan, Gatzen Michael, Kachulis Christopher J, Lennon Niall J, Brunette Charles A, Danowski Morgan E, Hauger Richard L, Garraway Isla P, Kibel Adam S, Lee Kyung M, Lynch Julie A, Maxwell Kara N, Ratner Dmitry, Rose Brent S, Teerlink Craig C, Xu George J, Hofherr Sean E, Lafferty Katherine A, Larkin Katie, Malolepsza Edyta, Patterson Candace J, Toledo Diana M, Donovan Jenny L, Hamdy Freddie C, Martin Richard M, Neal David E, Turner Emma L, Andreassen Ole A, Dale Anders M, Mills Ian G, Abraham Aswin, Batra Jyotsna, Clements Judith, Cussenot Olivier, Cybulski Cezary, Eeles Rosalind A, Fowke Jay H, Grindedal Eli Marie, Grönberg Henrik, Hamilton Robert J, Lim Jasmine, Lu Yong-Jie, MacInnis Robert J, Maier Christiane, Mucci Lorelei A, Multigner Luc, Neuhausen Susan L, Nielsen Sune F, Parent Marie-Élise, Park Jong Y, Petrovics Gyorgy, Plym Anna, Razack Azad, Rosenstein Barry S, Schleutker Johanna, Sørensen Karina Dalsgaard, Townsend Paul A, Travis Ruth C, Vega Ana, West Catharine M L, Wiklund Fredrik, Zheng Wei, Profile Steering Committee, IMPACT Study Steering Committee and Collaborators, PRACTICAL Consortium, VA Million Veteran Program, Seibert Tyler M

Аннотация

Precision healthcare aims to tailor disease prevention and early detection to individual risk. Prostate cancer screening may benefit from genomics-informed approaches. We developed and validated the P-CARE model, a prostate cancer risk prediction tool combining a polygenic score, family history and genetic ancestry, using data from over 585,000 male participants in the Million Veteran Program. The model was externally validated in diverse cohorts and implemented via a blended genome-exome assay for clinical use. Here we show that the P-CARE model identifies clinically meaningful gradients of prostate cancer risk among men, with higher scores associated with increased risk of any, metastatic and fatal prostate cancer. The model is now being used in a clinical trial of precision prostate cancer screening. This work demonstrates the potential for genomics-enabled health systems to improve prostate cancer screening and prevention in men. ClinicalTrials.gov registration: NCT05926102 .

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты